SummaryThis is a non-randomised trial with one experimental arm with several phases. All participants will first receive pembrolizumab administered intravenously (via IV) at a dose of 200mg on Day 1 of each 3-week cycle for 3 cycles. All participants will then undergo Positron Emission Tomography (PET) scans, and depending on these results, will receive one of two chemotherapy regimens. Some participants will receive AVD chemotherapy which involves doxorubicin in combination with vinblastine & dacarbazine, and other participants will receive escBEACOPP chemotherapy which involves etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone. Following chemotherapy, all participants will receive more pembrolizumab as consolidation therapy. This time, pembrolizumab will be administered via IV at a dose of 400mg on Day 1 of each 6-week cycle for 4 cycles.
This trial is treating patients with Hodgkin's lymphoma.
Use the hyperlinks, where available to access additional clinical trial information.
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)